Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000261233

Medchemexpress LLC 9H-Purine-2,8-diamine, 9-[(3R)-1-(cyclopropylsulfonyl)-3-pyrrolidinyl]-N2-[4-(4-methyl-1-pipera | 2463200-44-2 | 99.3% | C29H35N9O2S | 10MG
SDP

Catalog No. 5000261233
Encompass_Preferred

EGFR-IN-11 is a fourth-generation EGFR tyrosine kinase inhibitor that selectively targets triple-mutant EGFR (L858R/T790M/C797S). It suppresses EGFR phosphorylation, induces apoptosis, and arrests cells in G0/G1; reported potency against the triple mutant is IC50 = 18 nM, and the compound is supplied for preclinical research.

  • High potency against EGFR L858R/T790M/C797S (IC50 18 nM).
  • Suppresses EGFR phosphorylation and induces apoptosis.
  • Causes cell cycle arrest at G0/G1 phase.
  • Reported activity across multiple cancer cell lines.
  • High chemical purity (99.3%).

Catalog No. 50-002-61233 Supplier Medchemexpress LLC Supplier No. HY13061610MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

EGFR-IN-11 is a fourth-generation EGFR tyrosine kinase inhibitor that selectively targets triple-mutant EGFR (L858R/T790M/C797S). It suppresses EGFR phosphorylation, induces apoptosis, and arrests cells in G0/G1; reported potency against the triple mutant is IC50 = 18 nM, and the compound is supplied for preclinical research.

  • High potency against EGFR L858R/T790M/C797S (IC50 18 nM).
  • Suppresses EGFR phosphorylation and induces apoptosis.
  • Causes cell cycle arrest at G0/G1 phase.
  • Reported activity across multiple cancer cell lines.
  • High chemical purity (99.3%).

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.